Project Category : Metabolic Disorders
LATEST INDUSTRY PROJECTS IN METABOLIC DISORDERS
Januvia - DPP-IV inhibitor for Type 2 Diabetes
Januvia (sitagliptin phosphate) is an antihyperglycaemic drug...
Januvia (sitagliptin phosphate) is an antihyperglycaemic drug...
Lorcaserin, Investigational Oral Anti-Obesity Drug
Lorcaserin hydrochloride (Lorcaserin) is an investigative oral...
Lorcaserin hydrochloride (Lorcaserin) is an investigative oral...
Liraglutide - Next-Generation Antidiabetic Medication
Under development by Novo Nordisk, liraglutide is a member of...
Under development by Novo Nordisk, liraglutide is a member of...
Denosumab - Therapy for Prevention and Treatment of Osteoporosis
Amgen's denosumab (formerly AMG 162) is an investigational biological...
Amgen's denosumab (formerly AMG 162) is an investigational biological...
- Acomplia (Rimonabant) - Investigational Agent for the Management of Obesity,
- Byetta - First-in-Class Incretin Mimetic for Type 2 Diabetes,
- Cetilistat - Investigational Drug for Obesity,
- Denosumab - Therapy for Prevention and Treatment of Osteoporosis,
- Exubera - Inhaled Insulin for Type 1 and Type 2 Diabetes,
- Fablyn (Lasofoxifene) - Investigational SERM for the Prevention and Treatment of Osteoporosis,
- Galida - Dual PPAR Agonist for Type 2 Diabetes and Metabolic Syndrome,
- Galvus (vildagliptin) - DPP-IV Inhibitor / Oral Antidiabetic Agent,
- Januvia - DPP-IV inhibitor for Type 2 Diabetes,
- Liraglutide - Next-Generation Antidiabetic Medication,
- Lorcaserin, Investigational Oral Anti-Obesity Drug,
- Oral-Lyn - Oral Insulin for Type 1 and 2 Diabetes,
- Taranabant CB1 Receptor Inverse Agonist for Obesity,
- Tesofensine - Anti-Obesity Medication,
